Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results

By |2019-05-09T14:49:00-05:00May 9th, 2019|Categories: DSF Research Review|Tags: , , , , , , |

A number of publications have appeared recently reporting on the efficacy and safety of cannabidiol (CBD) as an add-on therapy, as its clinical trials are concluding and its use is extending.  This paper describes an "expanded access" program - that is, when the FDA allows access to a drug before approval.  This is of [...]